1
Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi, Paola LaColla: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, University of Cagliari, Centre National de la Recherche Scientifique, L Universite Montfellier II, Jones Day, October 27, 2009: US07608600 (69 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compos ...


2
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, Universita Degli Studi Di Cagliari, Jones Day, April 29, 2008: US07365057 (49 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and composi ...


3
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, December 22, 2009: US07635689 (47 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compos ...


4
Gilles Gosselin, Richard Storer, Paola LaColla, Jean Pierre Sommadossi: infections, 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, December 1, 2009: US07625875 (26 worldwide citation)

2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior resu ...


5
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari, Jones Day, June 16, 2009: US07547704 (26 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compos ...


6
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, Universita Degli Studi Di Cagliari, Madeline I Johnston Esq, King & Spalding, March 20, 2007: US07192936 (24 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and composi ...


7
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: infections, Modified 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, Universita Degli Studi di Cagliari, Jones Day, June 10, 2008: US07384924 (22 worldwide citation)

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and composi ...


8
Paola LaColla, Jean Pierre Sommadossi, Gilles Gosselin: infections, 2′ and 3′-nucleoside prodrugs for treating. Idenix Pharmaceuticals, University of Cagliari, Centre National de la Recherche Scientifique, L Universite Montpellier II, Jones Day, February 16, 2010: US07662798 (16 worldwide citation)

2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior resu ...


9
Jean Pierre Sommadossi, Paola LaColla: 2-C-methyl-3-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. King & Spalding, April 22, 2004: US20040077587-A1

The 3-L-valine ester of -D-2-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include th ...


10
Paola LaColla, Richard Storer, Gilles Gosselin, Jean Pierre Sommadossi: Modified 2 and 3-nucleoside prodrugs for treating flaviviridae infections. King & Spalding, February 8, 2007: US20070032407-A1

2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compos ...